Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01NEC
|
|||
| Former ID |
DNCL002430
|
|||
| Drug Name |
GSK2141795
|
|||
| Synonyms |
Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1], [2] | |
| Lymphoma [ICD-11: 2A80-2A86] | Phase 2 | [1], [2] | ||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C18H16Cl2F2N4O2
|
|||
| Canonical SMILES |
CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)NC(CC3=CC(=C(C=C3)F)F)CN)Cl
|
|||
| InChI |
1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1
|
|||
| InChIKey |
AXTAPYRUEKNRBA-JTQLQIEISA-N
|
|||
| CAS Number |
CAS 1047634-65-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7902). | |||
| REF 2 | ClinicalTrials.gov (NCT01958112) GSK1120212+GSK2141795 for Cervical Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7. | |||
| REF 4 | Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.